Comprehensive Summary
This review by Falkenbach et al discusses the benefits of prostate-specific membrane antigen imaging (PSMA)-PET/CT on risk stratification and individualized treatment options for those affected by prostate cancer. Utilizing PSA localization via PSMA-PET/CT can assist in determining the regions of cancer recurrence for intentional and direct treatment, with avoidance of systemic and more harmful methodologies. Furthermore, they discuss that the identification of distant metastases may assist in a decision to avoid harm to the genitourinary or gastrointestinal systems already suffering the effects of toxic treatments.
Outcomes and Implications
Up to half of patients who undergo definitive treatment of prostate cancer experience biochemical recurrence (BCR). This review describes the in-depth approach taken to better characterize those with potential BCR. While Falkenbach et al notes improvement upon previous methods, they express the current need for data with clear survival over long-term period. Utilizing PSMA-PET/CT allows healthcare providers to identify, localize, and strategize the most appropriate treatment plans to optimize patient care.